NFKB1 and diffuse large B-cell lymphoma: Derenzini et al. [25] used a targeted GEP panel combining the Lymph2Cx signature for COO classification, with additional targets including MYC, BCL-2, and NFKBIA (the latter encoding for the IkB-α protein, an endogenous inhibitor of NF-kB signaling [35]), in 186 FFPE cases originally diagnosed as DLBCL-NOS from two randomized trials (discovery cohorts NCT00355199 and NCT00499018) and in three independent validation cohorts.